Login / Signup

Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer.

Juan Luis Gomez MartiAzadeh NasrazadaniYing DingDaniel NormolleAdam M Brufsky
Published in: The oncologist (2023)
A subset of patients (10%) receiving trastuzumab in the metastatic setting have achieved long-term survival beyond 20 years.
Keyphrases
  • positive breast cancer
  • squamous cell carcinoma
  • phase ii study
  • small cell lung cancer
  • epidermal growth factor receptor
  • open label
  • metastatic breast cancer
  • phase iii
  • clinical trial
  • radiation therapy